ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis

Author(s): Wen Xu, Bei Wang, Yuxuan Cai, Jinlan Chen, Xing Lv, Chong Guo, Chengfu Yuan*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 23 , 2021

Become EABM
Become Reviewer
Call for Editor


Background: Long non-coding RNAs (lncRNA) have been identified as novel molecular regulators in cancers. LncRNA ADAMTS9-AS2 can mediate the occurrence and development of cancer through various ways, such as regulating miRNAs, activating the classical signaling pathways in cancer, and so on, which have been studied by many scholars. In this review, we summarize the molecular mechanisms of ADAMTS9-AS2 in different human cancers.

Methods: Through a systematic search of PubMed, lncRNA ADAMTS9-AS2 mediated molecular mechanisms in cancer are summarized inductively.

Results: ADAMTS9-AS2 aberrantly expression in different cancers is closely related to cancer proliferation, invasion, migration, and inhibition of apoptosis. The involvement of ADAMTS9-AS2 in DNA methylation, mediating PI3K / Akt / mTOR signaling pathways, and regulating miRNAs and proteins, shows its significant potential as a therapeutic cancer target.

Conclusion: LncRNA ADAMTS9-AS2 can become a promising biomolecular marker and a therapeutic target for human cancer.

Keywords: Long non-coding RNA, ADAMTS9-AS2, malignant tumors, therapeutic targets, DNA methylation, mediating PI3K.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 24 March, 2021
Page: [2722 - 2727]
Pages: 6
DOI: 10.2174/1381612827666210325105106
Price: $65

Article Metrics

PDF: 96